Clover Biopharmaceuticals Ltd. has announced positive preliminary Phase I clinical data for its combination respiratory PreF vaccine candidates targeting RSV, hMPV, and PIV3, utilizing its Trimer-Tag platform technology. The announcement covers results from two ongoing clinical trials: one in Australia evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in older adults, and another in the U.S. assessing re-vaccination with SCB-1019 in individuals previously vaccinated with GSK's AREXVY. Based on these results, Clover intends to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026. Additional data from the ongoing RSV re-vaccination trial is expected by the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.